InTandem Capital Invests in Clinilabs
InTandem Capital Partners (“InTandem Capital” or the “Firm”), a private equity firm specializing in healthcare services, has officially announced its strategic partnership with Clinilabs (the “Company”). Clinilabs is a global, full-service contract research organization (CRO) that provides a comprehensive suite of drug and device development services, with a specialized focus on central nervous system (CNS) disorders. The partnership is aimed at further expanding Clinilabs’ capabilities and accelerating its contributions to neuroscience therapeutics.
Since its inception in 2000, Clinilabs has emerged as a leader in CNS drug and device development, devoting its expertise to neurology, psychiatry, addiction, and rare CNS disorders. Over the past two decades, the company has built a strong reputation for its dedication to CNS therapeutics, which has allowed it to distinguish itself in an increasingly complex and evolving pharmaceutical landscape.
Gary Zammit, PhD, President & CEO of Clinilabs, expressed his enthusiasm for the partnership, stating, “I am pleased to announce that Clinilabs has partnered with InTandem to pursue the next stages of our growth. Clinilabs’ decision to partner came down to the people at InTandem. InTandem shares our vision for the Company, has deep expertise in the sector, and provides value-added operating resources that we sought to build our Company.”
Clinilabs has an impressive track record, having conducted over 750 CNS clinical trials since its founding. The company has played a pivotal role in the approval of 22 new therapies across 13 CNS indications, helping to bring life-changing treatments to patients in need. As a trusted CRO, Clinilabs has successfully undergone routine regulatory audits by global health authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, and the State Food and Drug Administration (sFDA) of China.
With a commitment to quality and innovation, Clinilabs has earned a reputation for being a therapeutically focused CRO that delivers highly specialized expertise and value to pharmaceutical, biotechnology, and medical technology clients. The company’s ability to manage complex clinical trials with efficiency and precision has made it an essential partner for organizations seeking to develop CNS therapeutics.
Mehran Ahmed, Partner at InTandem Capital, emphasized the significance of the partnership, noting the growing demand for CNS therapeutics. “As the market for CNS therapeutics continues to grow, it is essential for sponsors to work with a CRO that understands the unique challenges that come with neuroscience clinical trials. InTandem recognizes Clinilabs’ deep expertise, and we are thrilled to collaborate with Gary and his talented team. We look forward to supporting the Company in delivering high-quality, timely, and cost-effective drug and device development services that will accelerate the availability of new CNS therapeutics to the patients who need them most.”
The need for effective treatments for CNS disorders has never been greater. Conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, depression, schizophrenia, and epilepsy continue to present significant challenges to patients and healthcare providers. CNS clinical trials are particularly complex due to the intricacies of the human brain and the variability in patient responses. Factors such as the blood-brain barrier, disease progression, and symptom heterogeneity make CNS drug development uniquely demanding. Clinilabs’ extensive experience in navigating these challenges positions it as a key player in the field, ensuring that clinical trials are executed with the highest levels of precision and care.
The Company’s capabilities extend from first-in-human studies through the end of Phase 3 clinical trials. Its service offerings include trial management, feasibility and site selection, risk-based monitoring, data management, core laboratory services, biostatistics, medical writing, and trial execution at both its wholly-owned clinical units and independent investigator sites around the world. By providing end-to-end solutions, Clinilabs streamlines the clinical trial process and helps sponsors bring novel CNS therapies to market more efficiently.
One of Clinilabs’ key strengths is its ability to integrate advanced technologies into the clinical trial process. The company leverages digital health solutions, wearable devices, and artificial intelligence-driven analytics to enhance patient monitoring, improve data accuracy, and optimize trial outcomes. These innovations are particularly valuable in CNS research, where precise measurements and real-time patient assessments can significantly impact the success of a study.
Another critical aspect of Clinilabs’ approach is its patient-centric focus. CNS disorders often require long-term treatment strategies, and patient engagement is a crucial factor in the success of clinical trials. Clinilabs employs a range of strategies to enhance patient recruitment and retention, ensuring that studies are completed on time and within budget. The company works closely with patient advocacy groups, utilizes digital recruitment campaigns, and offers patient-friendly trial designs to improve participation rates.
Eileen McAuley, Chief Operating Officer at Clinilabs, highlighted the importance of the partnership for the company’s future. “This is an especially exciting time for our organization’s future. Our team remains focused on the ultimate measure of our success – improving the lives of patients who are fighting battles against central nervous system disorders.”
By partnering with InTandem Capital, Clinilabs is poised to expand its reach and enhance its service offerings. InTandem’s experience in scaling healthcare businesses and providing strategic guidance will play a crucial role in Clinilabs’ continued growth. The partnership will enable Clinilabs to invest in new technologies, expand its clinical site network, and strengthen its position as a leading CNS-focused CRO.
The investment also reflects InTandem Capital’s broader commitment to supporting healthcare companies that drive innovation and improve patient outcomes. The firm has a history of partnering with high-growth healthcare businesses, providing them with the capital and operational support needed to reach their full potential. By aligning with Clinilabs, InTandem is reinforcing its focus on the rapidly evolving field of neuroscience therapeutics, which is expected to experience significant growth in the coming years.
The global market for CNS therapeutics is projected to expand substantially, driven by an aging population, rising prevalence of neurological disorders, and advancements in medical research. Pharmaceutical and biotechnology companies are increasingly investing in CNS drug development, creating a strong demand for specialized CROs like Clinilabs. The company’s expertise, combined with InTandem’s strategic support, positions it well to capitalize on these opportunities and play a pivotal role in the advancement of CNS treatments.
As Clinilabs embarks on this new chapter, its leadership team remains committed to its mission of transforming neuroscience clinical research. The company will continue to build on its legacy of excellence, ensuring that patients suffering from CNS disorders have access to innovative therapies that can improve their quality of life.
